Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients

Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients
Tesaro will present three abstracts with results from the ENGOT-OV16/NOVA trial evaluating the effectiveness of Zejula (niraparib) in patients with recurrent ovarian cancer at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will also host an investor and analyst briefing to provide a business overview and an update on its product

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Cindy says:

    has anyone taken the drug Zejula for reoccurrence ovarian cancer my doctor has put me on it and I start taking it Monday just wanted to know the side effects that anyone has experience.

Leave a Comment

Your email address will not be published. Required fields are marked *